| Dr Barbara C Cavanaugh, MD | |
|
333 Cottman Ave, Philadelphia, PA 19111-2434 | |
| (215) 728-3883 | |
| Not Available |
| Full Name | Dr Barbara C Cavanaugh |
|---|---|
| Gender | Female |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 333 Cottman Ave, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023072212 | NPI | - | NPPES |
| 001227968 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | C1-0011490 (Delaware) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | MD033430E (Pennsylvania) | Primary |
| Entity Name | Medical Imaging Of Lehigh Valley Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134178023 PECOS PAC ID: 1557265212 Enrollment ID: O20040329001466 |
News Archive
By far, the most common injuries seen in emergency rooms in the United States are those affecting extremities. Immobilization is the most common treatment, and yet, until recently, it was unknown exactly why this technique worked to advance healing.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The idea is to teach the immune system of children at high risk for type 1 diabetes not to attack the insulin-producing cells of the pancreas.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Hepsera® (adefovir dipivoxil).
› Verified 5 days ago
| Entity Name | Fox Chase Cancer Center Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396019444 PECOS PAC ID: 8123289550 Enrollment ID: O20120412000054 |
News Archive
By far, the most common injuries seen in emergency rooms in the United States are those affecting extremities. Immobilization is the most common treatment, and yet, until recently, it was unknown exactly why this technique worked to advance healing.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The idea is to teach the immune system of children at high risk for type 1 diabetes not to attack the insulin-producing cells of the pancreas.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Hepsera® (adefovir dipivoxil).
› Verified 5 days ago
| Entity Name | Temple Faculty Practice Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881176949 PECOS PAC ID: 0345588711 Enrollment ID: O20190208002623 |
News Archive
By far, the most common injuries seen in emergency rooms in the United States are those affecting extremities. Immobilization is the most common treatment, and yet, until recently, it was unknown exactly why this technique worked to advance healing.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The idea is to teach the immune system of children at high risk for type 1 diabetes not to attack the insulin-producing cells of the pancreas.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Hepsera® (adefovir dipivoxil).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Barbara C Cavanaugh, MD 1601 Milltown Rd, Wilmington, DE 19808-4027 Ph: (302) 993-2330 | Dr Barbara C Cavanaugh, MD 333 Cottman Ave, Philadelphia, PA 19111-2434 Ph: (215) 728-3883 |
News Archive
By far, the most common injuries seen in emergency rooms in the United States are those affecting extremities. Immobilization is the most common treatment, and yet, until recently, it was unknown exactly why this technique worked to advance healing.
A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
The idea is to teach the immune system of children at high risk for type 1 diabetes not to attack the insulin-producing cells of the pancreas.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Sigmapharm Laboratories, LLC submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Hepsera® (adefovir dipivoxil).
› Verified 5 days ago
Joel M Stein, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-662-3005 | |
Dr. Sarah Denise Fenerty, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-7237 Fax: 215-707-9389 | |
Joanie M Garratt, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-662-3000 Fax: 215-662-7011 | |
Xin Qi Wei, DO Radiology Medicare: Medicare Enrolled Practice Location: 160 E Erie Ave, Philadelphia, PA 19134 Phone: 215-427-5234 | |
Ryan Mcclintock, MD Radiology Medicare: Medicare Enrolled Practice Location: 3400 Spruce Street, Philadelphia, PA 19104 Phone: 215-662-3000 Fax: 215-662-7011 | |
Dr. David P. Friedman, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 111 S 11th St, Suite 3390, Philadelphia, PA 19107 Phone: 215-955-2900 Fax: 215-923-1562 | |
Michel Bilello, MD, PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, 1 Silverstein, Philadelphia, PA 19104 Phone: 215-662-3005 |